ALPENGLOW BIOSCIENCES, INC.
Seattle, WA · Founded 2018 · CIK 0001763787 · Medtech · Private
3D open-top light-sheet microscopy system with machine learning analysis pipeline for quantifying liver fibrosis in NASH diagnosis
lightspeedmicro.com →- Grants
- $3.4M
- 6 awards
- Sector median: 1
- Raised
- $6.8M
- 4 Form D · Mar 2024
- 30 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Open-top light-sheet microscopy for non-destructive 3D pathology of prostate biopsies | $397,742 | |
| Private capital raised | Form D · SEC | $4,582,788 | |
| Federal grant | Department of Health and Human Services · Phase I · Same-day Breast Pathology Results using Open-Top Light-Sheet Microscopy for Image-guided Core Needle Biopsies | $398,305 | |
| Federal grant | Department of Health and Human Services · Phase I · 3D quantification of NASH-related liver fibrosis using open-top light-sheet microscopy | $269,351 | |
| Federal grant | Department of Health and Human Services · Phase I · 3D diagnosis of Hirschsprung disease using open-top light-sheet microscopy | $252,522 | |
| Private capital raised | Form D · SEC | $1,800,000 | |
| Federal grant | Department of Health and Human Services · Phase II · 3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk Patients | $994,370 | |
| Federal grant | Department of Health and Human Services · Phase II · 3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk Patients | $1,051,446 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1392 | HEALTH DISCOVERY LABS LLC | — | — |
| 1393 | DYMEDIX DIAGNOSTICS, INC. | — | $2.1M |
| 1394 | SUTUREGARD Medical, Inc. | — | $3.8M |
| 1395 | ALPENGLOW BIOSCIENCES, INC. | — | $6.8M |
| 1396 | Marrow Access Technologies, Inc. | — | $611K |
| 1397 | AerBetic, Inc. | — | $100K |
| 1398 | Hura Imaging, Inc. | — | $250K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Steven BuckleyDirector · Executive Officer
- Michael DuttonExecutive Officer
- Daniella KranjacDirector
- Jonathan LiuDirector
- Gustavo MahlerDirector
- Nicholas RederDirector · Executive Officer
- Alex SpringerExecutive Officer
Patents
- Apparatuses, Systems, And Methods For Processing Of Three Dimensional Optical Microscopy Image Dataapplication
- Apparatuses, Systems, And Methods For Processing Of Three Dimensional Optical Microscopy Image Dataapplication
- Apparatuses, Systems, And Methods For Processing Of Three Dimensional Optical Microscopy Image Dataapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.